Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

4D-150

Gene therapy (AAV vector) · Gene silencing: VEGF-C · developed by 4D Molecular Therapeutics

Phase 3 Most advanced trial

3 Registered trials

What is 4D-150?

4D-150 is an AAV-based gene therapy delivered by intravitreal injection. It carries a microRNA that targets VEGF-C and a codon-optimized sequence encoding aflibercept. It is being studied in diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Gene therapy (AAV vector)
Targets: VEGF-C (secondary target)
Mechanism: Gene silencing: VEGF-C
Pathways: VEGF-C silencing via microRNA, VEGF-A and PlGF sequestration by encoded aflibercept
Therapy area: Ophthalmology
Developer: 4D Molecular Therapeutics
In trials of: FDMT
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07867080	Phase 3	Diabetic Macular Edema (DME)	Recruiting	FDMT
NCT07064759	Phase 3	Neovascular Age-Related Macular Degeneration (nAMD)	Recruiting	FDMT
NCT05930561	Phase 2	Diabetic Macular Edema	Active not recruiting	FDMT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetic Macular EdemaDiabetic Macular Edema (DME)Diabetic RetinopathyNeovascular Age-Related Macular Degeneration (nAMD)

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z